WO2015173813A1 - Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes - Google Patents
Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes Download PDFInfo
- Publication number
- WO2015173813A1 WO2015173813A1 PCT/IL2015/050499 IL2015050499W WO2015173813A1 WO 2015173813 A1 WO2015173813 A1 WO 2015173813A1 IL 2015050499 W IL2015050499 W IL 2015050499W WO 2015173813 A1 WO2015173813 A1 WO 2015173813A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenylpropanamide
- propan
- hydroxyphenyl
- hydroxypropoxy
- pharmaceutical composition
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 54
- CDKPAWCGPQDCGU-UHFFFAOYSA-N n-[1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl]-3-phenylpropanamide Chemical compound C=1C=CC=CC=1CCC(=O)NC(COCC(O)C)CC1=CC=C(O)C=C1 CDKPAWCGPQDCGU-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 230000002265 prevention Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 44
- CDKPAWCGPQDCGU-LPHOPBHVSA-N n-[(2s)-1-(4-hydroxyphenyl)-3-[(2s)-2-hydroxypropoxy]propan-2-yl]-3-phenylpropanamide Chemical group C([C@@H](COC[C@@H](O)C)NC(=O)CCC=1C=CC=CC=1)C1=CC=C(O)C=C1 CDKPAWCGPQDCGU-LPHOPBHVSA-N 0.000 claims description 43
- CDKPAWCGPQDCGU-APWZRJJASA-N n-[(2s)-1-(4-hydroxyphenyl)-3-[(2r)-2-hydroxypropoxy]propan-2-yl]-3-phenylpropanamide Chemical compound C([C@@H](COC[C@H](O)C)NC(=O)CCC=1C=CC=CC=1)C1=CC=C(O)C=C1 CDKPAWCGPQDCGU-APWZRJJASA-N 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010022489 Insulin Resistance Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 201000001421 hyperglycemia Diseases 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 230000002503 metabolic effect Effects 0.000 claims description 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000028389 Nerve injury Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 208000002787 Pregnancy Complications Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000021921 corneal disease Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 208000011661 metabolic syndrome X Diseases 0.000 claims description 4
- 230000008764 nerve damage Effects 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000012113 pregnancy disease Diseases 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 208000029257 vision disease Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 42
- 102000004877 Insulin Human genes 0.000 description 21
- 108090001061 Insulin Proteins 0.000 description 21
- 229940125396 insulin Drugs 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004190 glucose uptake Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- -1 picric Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000003746 Insulin Receptor Human genes 0.000 description 4
- 108010001127 Insulin Receptor Proteins 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- 229960001466 acetohexamide Drugs 0.000 description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- CDKPAWCGPQDCGU-CVMIBEPCSA-N n-[(2s)-1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl]-3-phenylpropanamide Chemical compound C([C@@H](COCC(O)C)NC(=O)CCC=1C=CC=CC=1)C1=CC=C(O)C=C1 CDKPAWCGPQDCGU-CVMIBEPCSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 2
- 108010033693 saxagliptin Proteins 0.000 description 2
- 230000000580 secretagogue effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000261 subcutaneous preadipocyte Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 229960001254 vildagliptin Drugs 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940089126 diabeta Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- BOVGTQGAOIONJV-UHFFFAOYSA-N gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940120105 glynase Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CDKPAWCGPQDCGU-VQIMIIECSA-N n-[(2r)-1-(4-hydroxyphenyl)-3-[(2r)-2-hydroxypropoxy]propan-2-yl]-3-phenylpropanamide Chemical compound C([C@H](COC[C@H](O)C)NC(=O)CCC=1C=CC=CC=1)C1=CC=C(O)C=C1 CDKPAWCGPQDCGU-VQIMIIECSA-N 0.000 description 1
- CDKPAWCGPQDCGU-QFBILLFUSA-N n-[(2r)-1-(4-hydroxyphenyl)-3-[(2s)-2-hydroxypropoxy]propan-2-yl]-3-phenylpropanamide Chemical compound C([C@H](COC[C@@H](O)C)NC(=O)CCC=1C=CC=CC=1)C1=CC=C(O)C=C1 CDKPAWCGPQDCGU-QFBILLFUSA-N 0.000 description 1
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940001450 onglyza Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940096058 prandin Drugs 0.000 description 1
- 229940095885 precose Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 210000003207 subcutaneous adipocyte Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229940035266 tolinase Drugs 0.000 description 1
- 229940049667 tradjenta Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to pharmaceutical composition
- pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide for the treatment of type II diabetes and/or other medical conditions associated with therewith.
- Diabetes mellitus is considered as a worldwide epidemic.
- the International Diabetes Federation's most recent estimates indicate that 8.3% of adults - 382 million people - have diabetes, and the number of people with this disease is set to rise beyond 592 million in less than 25 years.
- IDDM insulin dependent diabetes mellitus
- NIDDM non-insulin dependent diabetes mellitus
- Type I diabetes is considered as an autoimmune disease, results from an immune destruction of the ⁇ -cells of the pancreas. Although the exact cause is unknown, evidence suggests that both genetic predisposition and environmental factors, such as viral infection, are involved.
- the prevalent treatment for type I diabetes is administration of exogenous insulin.
- Type II diabetes accounts for about 90% of those with diabetes. Unlike type I diabetes, this is a metabolic disease which is characterized by hyperglycemia (high blood glucose levels) due to insulin resistance and insulin deficiency. Several risk factors have been associated with type II diabetes, including obesity, advancing age, genetic susceptibility, high blood pressure, and life style patterns (such as physical inactivity, smoking and alcohol). Type II diabetes progresses through three stages of the disease. The first stage is known as a "pre-diabetic" state and involves hyperinsulinemia and "primary" insulin resistance. In this phase, cells no longer respond properly to insulin, the pancreas compensates for this resistance by producing more insulin. The insulin responsiveness in this stage is sufficient to maintain normal glucose tolerance or partially impaired glucose tolerance.
- insulin resistance worsens such that blood glucose levels abnormally rise after a meal despite elevated insulin levels (this condition is known as "postprandial hyperglycemia").
- postprandial hyperglycemia this condition is known as "postprandial hyperglycemia”
- insulin resistance does not change, however, the elevated glucose levels further damage ⁇ -cells, thereby drastically reducing insulin secretion and causing overt diabetes. This is made evident by "fasting hyperglycemia", in which glucose levels are high most of the time.
- fasting hyperglycemia in which glucose levels are high most of the time.
- the mechanism of insulin resistance is not fully understood. However, several observations have suggested that insulin resistance is due, at least in part, to inhibition of the insulin receptor.
- insulin-receptor function Deficiencies of insulin-receptor function might lead to decrease in the insulin-stimulated activities which include, for example, insulin receptor autophosphorylation and insulin receptor- mediated kinase activities (such as tyrosine kinase).
- insulin receptor autophosphorylation and insulin receptor- mediated kinase activities (such as tyrosine kinase).
- insulin receptor- mediated kinase activities such as tyrosine kinase
- N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide is disclosed in U.S. 7,642,290 for the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection.
- U.S. 7,674,829 discloses the stereoisomers of (S)N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide in the treatment of AIDS and other viral diseases.
- U.S.2011/0086910 discloses the use of N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the treatment or prevention of pain.
- the present invention relates to pharmaceutical composition
- pharmaceutical composition comprising stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide (formula I) for the treatment of type II diabetes and related medical conditions.
- the present invention relates to the use of substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide, or substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, or combination thereof, for the treatment of type II diabetes and/or a medical condition associated with this disease.
- the present invention is based in part on the unexpected discovery that the (S,S) and (S,R) diastereomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2- yl)-3 -phenylpropanamide, namely N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and N-((S)- 1 -(4-hydroxyphenyl)- 3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide both individually induce cellular intake of glucose, in vitro.
- N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2- yl)-3 -phenylpropanamide and N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide have the ability to mimic the metabolic insulin action through independent activation of insulin receptor. This may be accomplished by the activation of the tyrosine kinase Lyn with either one or both of the compounds of the present invention.
- the activated kinase phosphorylates the insulin receptor substrate 1 (IRS-1), which triggers several signaling pathways that are involved in the regulation of glucose production, transportation, and cellular utilization.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent for use in the treatment of type II diabetes and/or a medical condition associated with type II diabetes.
- the N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is in the form of a substantially pure stereoisomer or a combination of stereoisomers.
- said N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is selected from N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((S)- l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and a combination thereof.
- the N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2- yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.
- the N-(l- (4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide.
- the stereoisomer comprises at least about 90% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 10% of other stereoisomeric forms of the compound.
- the stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-
- the stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-
- the composition is in the form of a capsule, tablet, granule, powder, solution or suspension.
- the pharmaceutical composition is in a form suitable for intravenous, intramuscular, oral, sublingual, buccal, parenteral, intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal administration.
- the present invention contemplates a method for treating type II diabetes and/or a medical condition associated with type II diabetes in a subject in need thereof, comprising the step of administering to said subject a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent.
- said treating comprises any one or more of alleviating, preventing, delaying the onset, attenuating the progression of type II diabetes or conditions associated with this disease and achieving a beneficial therapeutic effect for a sustained period of time.
- the medical condition associated with type II diabetes is selected from the group consisting of hyperglycemia, insulin resistance, impaired glucose tolerance, fatty liver, metabolic syndrome X, obesity, cancer, microvascular complications including neuropathy (nerve damage), nephropathy (kidney disease), vision disorders (e.g., retinopathy, glaucoma, cataract and corneal disease), macrovascular complications including heart disease, stroke, peripheral vascular disease, infections, metabolic difficulties, impotence, autonomic neuropathy and pregnancy complications.
- neuropathy nerve damage
- nephropathy kidney disease
- vision disorders e.g., retinopathy, glaucoma, cataract and corneal disease
- macrovascular complications including heart disease, stroke, peripheral vascular disease, infections, metabolic difficulties, impotence, autonomic neuropathy and pregnancy complications.
- the subject is a mammal, preferably a human.
- the present invention relates to the use of a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide as described herein, for the manufacture of a medicament for treating type II diabetes and/or a medical condition associated with type II diabetes.
- Figs. 1A-1D show Oil-Red stained human subcutaneous pre-adipocytes (A xlO; B x20) and human subcutaneous differentiated adipocytes (C xlO; D x20).
- Figs. 2A-2B are bar charts representing the glucose uptake level in adipocytes, in vitro, in the presence of different concentrations of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide (Fig. 2A; (S,S); relative to insulin performance) and N-((S)- l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2- yl)-3 -phenylpropanamide (Fig. 2B; (S,R); relative to insulin performance).
- the two left columns depict control experiments, in which cultures were treated with 100 nM insulin or 10 ⁇ of Rosiglitazone.
- the present invention relates to pharmaceutical compositions comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide for use in the treatment of type II diabetes and/or related medical conditions, e.g., hyperglycemia, insulin resistance and impaired glucose tolerance, among others.
- type II diabetes and/or related medical conditions e.g., hyperglycemia, insulin resistance and impaired glucose tolerance, among others.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent for use in the treatment of type II diabetes and/or a medical condition associated with type II diabetes.
- the N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is in the form of a substantially pure stereoisomer or a combination of stereoisomers.
- said N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is selected from N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((S)- l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and a combination thereof.
- the N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2- yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.
- the N-(l- (4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide.
- the composition of the invention comprises a combination of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and N-((S)- 1 -(4-hydroxyphenyl)- 3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.
- stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
- enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another. Enantiomers have identical chemical and physical properties except for their ability to rotate plane- polarized light (+/-) by equal amounts but in opposite directions.
- Diastereomers refers to stereoisomers with two or more centers of asymmetry and whose molecules are not mirror images of one another.
- Diastereomers are characterized by differences in physical properties (e.g., melting points, boiling points and spectral properties) and by some differences in chemical behavior towards achiral as well as chiral reagents.
- the terms "diastereomers” and “diastereoisomer” as used herein, are interchangeable.
- All stereoisomers of the compound of the instant invention are contemplated, either in admixture or in pure or substantially pure form.
- the compound can exist in enantiomeric and/or diastereomeric forms or in mixtures thereof.
- the present invention intends to the use of any enantiomerically or diastereomerically enriched mixtures (i.e., mixtures enriched for one enantiomer or diastereomer), substantially pure enantiomers or diastereomers, or any mixtures thereof.
- the chiral centers can be designated as R or S.
- the compound of the invention may be present as a salt.
- salt encompasses both basic and acid addition salts, including but not limited to phosphate, dihydrogen phosphate, hydrogen phosphate and phosphonate salts, and include salts formed with organic and inorganic anions and cations. Furthermore, the term includes salts that form by standard acid-base reactions of basic groups and organic or inorganic acids.
- Such acids include hydrochloric, hydrofluoric, hydrobromic, trifluoroacetic, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, cholic, pamoic, mucic, D-camphoric, phthalic, tartaric, salicyclic, methanesulfonic, benzenesulfonic, p- toluenesulfonic, sorbic, picric, benzoic, cinnamic, and like acids.
- Additional salts of the compound described herein may be prepared by reacting the parent molecule with a suitable base, e.g., NaOH or KOH to yield the corresponding alkali metal salts, e.g., the sodium or potassium salts.
- a suitable base e.g., NaOH or KOH
- Additional basic addition salts include ammonium salts (NH/t + ), substituted ammonium salts, Li, Ca, Mg, salts, and the like.
- the compound of the invention may be present as a hydrate.
- hydrate refers to a solvate wherein the solvent molecule is water.
- Solvate contemplates a physical association of the compound of the invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation.
- substantially pure generally refers to the presence of at least about 80% of a single stereoisomer, preferably at least about 90% more preferably at least about 95% or 97% and most preferably at least about 98% or 99% of a single stereoisomer.
- the compositions of the invention comprise substantially pure N-((S)- 1 -(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide.
- the substantially pure stereoisomer comprises at least about 80% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 20% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 90% by weight of N-((S)- 1 -(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide, and less than about 10% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3- ((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 5% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 97% by weight of N-((S)- 1 -(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide, and less than about 3% of other stereoisomeric forms of the compound. According to yet other preferred embodiments, the substantially pure stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3- ((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 2% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 99% by weight of N-((S)-1- (4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 1 % of other stereoisomeric forms of the compound.
- compositions of the invention comprise substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide.
- the substantially pure stereoisomer comprises at least about 80% by weight of N-((S)-l-(4-hydroxyphenyl)-3- ((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 20% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 90% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 10% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 5% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 97% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 3% of other stereoisomeric forms of the compound. According to yet other preferred embodiments, the substantially pure stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 2% of other stereoisomeric forms of the compound.
- the substantially pure stereoisomer comprises at least about 99% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 1 % of other stereoisomeric forms of the compound.
- compositions of the invention comprise a mixture of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide and N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.
- the stereoisomer comprises at least about 80% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or N- ((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or a combination thereof, and less than about 20% of other stereoisomeric forms of the compound.
- the stereoisomer comprises at least about 90% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 10% of other stereoisomeric forms of the compound.
- the stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 5% of other stereoisomeric forms of the compound.
- the stereoisomer comprises at least about 97% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 3% of other stereoisomeric forms of the compound.
- the stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 2% of other stereoisomeric forms of the compound.
- the stereoisomer comprises at least about 99% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 1% of other stereoisomeric forms of the compound.
- the at least one other stereoisomer is selected from the group consisting of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((S)- 1 -(4-hydroxyphenyl)-3- ((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((R)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((R)- l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or combination thereof.
- WO 2013/084238 discloses a stereochemically controlled synthesis of N-((S)-l-(4-hydroxyphenyl)-3- ((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide. The prevailing racemization was overcome by controlling the reaction temperature and the order of adding the raw materials.
- WO 2013/084238 also demonstrates a method of separation of the two diastereomers prepared as a mixture in the traditional synthesis (described for example, in US 2011/0086910), by a supercritical fluid chromatography (SFC) on RegisPackTM, a polysaccharide coated chiral column.
- SFC supercritical fluid chromatography
- RegisPackTM a polysaccharide coated chiral column
- the present invention provides a method for treating type II diabetes and/or a medical condition associated with type II diabetes in a subject in need thereof, comprising the step of administering to said subject a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent.
- treating and “treatment”, as used herein are interchangeable and refer to any one or more of delaying the onset of, retarding or reversing the progress of, alleviating or preventing either type II diabetes or one or more medical conditions associated with of such disease, and achieving a beneficial therapeutic effect preferably for a sustained or prolonged period of time.
- treating and “treatment”, as used herein are interchangeable and refer to any one or more of delaying the onset of, retarding or reversing the progress of, alleviating or preventing either type II diabetes or one or more medical conditions associated with of such disease, and achieving a beneficial therapeutic effect preferably for a sustained or prolonged period of time.
- the medical condition associated with type II diabetes is selected from the group consisting of glucose and insulin metabolism deficiencies, diabetic complications and metabolic disorders.
- Non limiting examples of medical conditions associated with type II diabetes include hyperglycemia, insulin resistance, impaired glucose tolerance, fatty liver, metabolic syndrome X, obesity, cancer, microvascular complications including neuropathy (nerve damage), nephropathy (kidney disease) and vision disorders (e.g., retinopathy, glaucoma, cataract and corneal disease), macrovascular complications including heart disease, stroke and peripheral vascular disease (which can lead to ulcers, gangrene and amputation) among others.
- neuropathy nerve damage
- nephropathy kidney disease
- vision disorders e.g., retinopathy, glaucoma, cataract and corneal disease
- macrovascular complications including heart disease, stroke and peripheral vascular disease (which can lead to ulcers, gangrene and amputation) among others.
- Type II diabetes Other medical conditions associated with type II diabetes, include but are not limited to, infections, metabolic difficulties, impotence, autonomic neuropathy and pregnancy complications.
- administering refers to bringing in contact with a compound of the present invention. Administration can be accomplished to cells or tissue cultures, or to living organisms, for example humans.
- the subject is a mammal, preferably a human.
- the present invention relates to the use of a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide as described herein, in the manufacture of a medicament for treating type II diabetes and/or a medical condition associated with type II diabetes.
- the method of treatment of the invention may be in parallel to, prior to, or following additional method of treatment.
- the composition of the present invention may be administered to a subject in need as a prodrug.
- the prodrug often offers advantages such as delayed release, solubility, and/or tissue compatibility.
- the term "prodrug”, as used herein, refers to the compound of the present invention that when administered generates the biologically active "drug'Vcomposition as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s).
- the prodrug and derivatives thereof may be prepared by methods and techniques known to those of skill in the art.
- the present invention further provides the administration of the pharmaceutical compositions of the present invention in combination with at least one additional antidiabetic medication.
- the combination therapy may be administered to the subject undergoing treatment simultaneously or sequentially in any order, at a time interval determined by a skilled artisan.
- Non-limiting examples of anti-diabetic medication include insulin, secretagogues (such as sulfonylureas and nonsulfonylurea secretagogues), alpha-glucosidase inhibitors, biguanides, meglitinides, and thiazolidinediones, sensitizers (such as biguanides and thiazolidinediones), peptide analogs (such as injectable incretin mimetics and injectable Amylin analogues), among others.
- secretagogues such as sulfonylureas and nonsulfonylurea secretagogues
- alpha-glucosidase inhibitors biguanides, meglitinides, and thiazolidinediones
- sensitizers such as biguanides and thiazolidinediones
- peptide analogs such as injectable incretin mimetics and injectable Amylin analogues
- Non-limiting examples of known anti-diabetic drugs include Metformin, rosiglitazone (Avandia), pioglitazone (Actos), tolbutamide (Orinase),acetohexamide (Dymelor), tolazamide (Tolinase), chlorpropamide (Diabinese), Second-generation agents, glipizide (Glucotrol), glyburide (Diabeta, Micronase, Glynase), glimepiride (Amaryl), gliclazide (Diamicron), repaglinide (Prandin), nateglinide (Starlix), miglitol (Glyset), acarbose (Precose/Glucobay), Exenatide, Liraglutide, vildagliptin (Galvus), sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta) among
- the pharmaceutical composition of the present invention can be formulated for administration by a variety of routes selected from the group consisting of intravenous, intramuscular, oral, sublingual, buccal, parenteral, , intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal among others.
- routes selected from the group consisting of intravenous, intramuscular, oral, sublingual, buccal, parenteral, , intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal among others.
- routes selected from the group consisting of intravenous, intramuscular, oral, sublingual, buccal, parenteral, , intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal among others.
- composition is prepared in a manner well known in the pharmaceutical art and comprise as the active ingredient one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide as described hereinabove, and a pharmaceutically acceptable excipient and/or carrier.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U. S. Pharmacopeia or other generally recognized pharmacopeia for use in animals and, more particularly, in humans.
- composition of the invention is suitable for use in a variety of drug delivery systems as detailed hereinbelow.
- Pharmaceutically acceptable carriers suitable for use in the present invention may be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985).
- the active ingredient is usually mixed with a carrier and/or excipient, which may be a solid, semi-solid, or liquid material.
- a carrier and/or excipient which may be a solid, semi-solid, or liquid material.
- the composition is preferably suited for oral administration, in which case it may be in the form of a tablet, pill, pellet, chewable tablet, capsule, granule, powder, lozenge, sachet, cachet, elixir, suspension, transdermal patch, dispersion, emulsion, solution, syrup, intranasal spray, aerosol (as a solid or in a liquid medium), ointment (containing, for example, up to 10% by weight of the active compound), soft and hard gelatin capsule, suppositorie, sterile injectable solution and sterile packaged powder among other.
- the compound of the present invention may be added to a person's diet by mixing them with food or drink.
- the carrier may be any of those conventionally used. The choice of carrier will be determined by the particular method used to administer the pharmaceutical composition. Some examples of suitable carriers include lactose, glucose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water and methylcellulose. Other pharmaceutical carriers may be sterile liquids, such as water, alcohols (e.g., ethanol) and lipid carriers such as oils (including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like), phospholipids (e.g.
- lecithin polyethylene glycols, glycerine, propylene glycol or other synthetic solvents.
- Water is a preferred carrier when the pharmaceutical composition is administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- the formulations may additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents, surfactants, emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; flavoring agents, colorants, buffering agents (e.g., acetates, citrates or phosphates), disintegrating agents, moistening agents and agents for the adjustment of tonicity such as sodium chloride. Fatty acids may also be included.
- Alternative formulations include immediate-release formulations, slow-release formulations, controlled-release formulations, sustained-release formulations, extended-release formulations, delayed-release formulations and the like, as are known in the art. Each possibility is a separate embodiment of the invention.
- the amount of the active ingredient that will be effective in the treatment of type II diabetes will depend on the severity of the disease, and may be determined by standard non-clinical or clinical techniques.
- the precise dose to be employed in the formulation will also depend on the route of administration, the seriousness of the disease, and should be decided according to the judgment of the practitioner and each patient's circumstances.
- a preferred dosage will be within the range of 0.01-1000 mg/kg of body weight, more preferably, about 0.1 mg/kg to about 100 mg/kg and even more preferably about 1 mg/kg to about 10 mg/kg.
- Applicable methods for determining an appropriate dose and dosing schedule for administration of the present invention are known in the art and are described, for example, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Brunton. L., Chabner B., and Knollman B., McGraw-Hill (2006), and in Remington: The Science and Practice of Pharmacy, Troy D. B., and Beringer P., Lippencott Williams & Wilkins (2003)
- Example 1 The effect of N- «S)-l-(4-hydroxyphenyl)-3- «S)-2- hvdroxypropoxy)propan-2-yl)-3-phenylpropanamide and N-((S)-l-(4- hvdroxyphenyl)-3-((R)-2-hvdroxypropoxy)propan-2-yl)-3-phenylpropanamide on glucose uptake in vitro
- N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide and N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide were provided by Novaremed. Each compound was dissolved in DMSO (10 mM stock solution) and stored at -20°C until use.
- Human Subcutaneous Preadipocytes isolated from human subcutaneous fat tissues were purchased from Innoprot. The cells were cultured in preadipocyte medium in 96 well plates in a humidified atmosphere of 5% CO2 at 37 °C. After confluence, the cells were incubated in differentiation medium for two days. The medium was then changed to Dulbecco's Modified Eagle medium (DMEM), a medium containing 10 ⁇ g/ml insulin, for another two days. The cells were allowed to differentiate for six days before glucose uptake experiments. As shown in Figure 1 , pre- adipocytes (Fig. 1A; xlO and Fig. IB; x20) and differentiated adipocytes (Fig. 1C; xlO and Fig.
- DMEM Dulbecco's Modified Eagle medium
- Control cultures were treated with 100 nM insulin or 10 ⁇ of Rosiglitazone (RGT), a PPARy agonist. After incubation, free 2-NBDG was washed out from the cultures and the remaining fluorescence monolayer in the cell was measured with a Tecan-GENios fluorescence reader (Tecan). Excitation wavelength was set to 460 nm and an emission wavelength to 540 nm. Values of 2-NBDG incorporation in the absence of insulin were subtracted from those obtained with 100 nM insulin to establish 100% of specific 2-NBDG uptake.
- RTT Rosiglitazone
- Figures 2A-B demonstrate that both compounds induced glucose uptake in a biphasic manner.
- N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide may be therapeutically advantageous over N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2- yl)-3-phenylpropanamide (Fig. 2A) as with merely 0.25 ⁇ of the former a substantial glucose uptake was achieved, while a similar effect was obtained with about 100 ⁇ of the later.
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to pharmaceutical composition comprising one or more stereoisomers of N-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide for the the treatment of type II diabetes and/or other medical conditions associated with this disease.
Description
PHARMACEUTICAL COMPOSITION COMPRISING STEREOISOMERS OF N-(l-(4-HYDROXYPHENYL)-3-(2-HYDROXYPROPOXY)PROPAN-2-YL)-3- PHENYLPROPANAMIDE FOR THE PREVENTION AND TREATMENT
OF TYPE II DIABETES
FIELD OF THE INVENTION
The present invention relates to pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide for the treatment of type II diabetes and/or other medical conditions associated with therewith.
BACKGROUND OF THE INVENTION
Diabetes mellitus is considered as a worldwide epidemic. The International Diabetes Federation's most recent estimates indicate that 8.3% of adults - 382 million people - have diabetes, and the number of people with this disease is set to rise beyond 592 million in less than 25 years.
There are two main clinical forms of diabetes, each with a different pathogenesis: type I, insulin dependent diabetes mellitus (IDDM) and type II, non-insulin dependent diabetes mellitus (NIDDM).
Type I diabetes is considered as an autoimmune disease, results from an immune destruction of the β-cells of the pancreas. Although the exact cause is unknown, evidence suggests that both genetic predisposition and environmental factors, such as viral infection, are involved. The prevalent treatment for type I diabetes is administration of exogenous insulin.
Type II diabetes accounts for about 90% of those with diabetes. Unlike type I diabetes, this is a metabolic disease which is characterized by hyperglycemia (high blood glucose levels) due to insulin resistance and insulin deficiency. Several risk factors have been associated with type II diabetes, including obesity, advancing age, genetic susceptibility, high blood pressure, and life style patterns (such as physical inactivity, smoking and alcohol). Type II diabetes progresses through three stages of the disease. The first stage is known as a "pre-diabetic" state and involves hyperinsulinemia and "primary" insulin resistance. In this phase, cells no longer
respond properly to insulin, the pancreas compensates for this resistance by producing more insulin. The insulin responsiveness in this stage is sufficient to maintain normal glucose tolerance or partially impaired glucose tolerance. In the second stage, insulin resistance worsens such that blood glucose levels abnormally rise after a meal despite elevated insulin levels (this condition is known as "postprandial hyperglycemia"). In the third or late phase of type II diabetes, insulin resistance does not change, however, the elevated glucose levels further damage β-cells, thereby drastically reducing insulin secretion and causing overt diabetes. This is made evident by "fasting hyperglycemia", in which glucose levels are high most of the time. The mechanism of insulin resistance is not fully understood. However, several observations have suggested that insulin resistance is due, at least in part, to inhibition of the insulin receptor. Deficiencies of insulin-receptor function might lead to decrease in the insulin-stimulated activities which include, for example, insulin receptor autophosphorylation and insulin receptor- mediated kinase activities (such as tyrosine kinase). Thus, although the receptor can bind insulin, the normal insulin-mediated transduction signals are not transmitted.
The compound N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide is disclosed in U.S. 7,642,290 for the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection.
U.S. 7,674,829 discloses the stereoisomers of (S)N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide in the treatment of AIDS and other viral diseases.
U.S.2011/0086910 discloses the use of N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the treatment or prevention of pain.
These stereoisomers of (S)N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide are further disclosed in U.S. 2014/0039060 for treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders.
Isolated stereoisomers of (S,S) and (S,R), are disclosed in WO 2013/084238, in particular the use of the stereoisomer N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is disclosed for the treatment or prevention of pain.
There is a need for an effective anti-diabetic drug to treat the disease and other medical conditions associated with type II diabetes. Ideally, this therapeutic agent should mimic the ordinary insulin metabolic action with minimal adverse side effects.
SUMMARY OF THE INVENTION
The present invention relates to pharmaceutical composition comprising stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide (formula I) for the treatment of type II diabetes and related medical conditions.
In one embodiment, the present invention relates to the use of substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide, or substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, or combination thereof, for the treatment of type II diabetes and/or a medical condition associated with this disease.
The present invention is based in part on the unexpected discovery that the (S,S) and (S,R) diastereomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2- yl)-3 -phenylpropanamide, namely N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and N-((S)- 1 -(4-hydroxyphenyl)- 3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide both individually induce cellular intake of glucose, in vitro.
Without wishing to be limited by any particular theory or mechanism of action, it is hypothesized that N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2- yl)-3 -phenylpropanamide and N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-
hydroxypropoxy)propan-2-yl)-3-phenylpropanamide have the ability to mimic the metabolic insulin action through independent activation of insulin receptor. This may be accomplished by the activation of the tyrosine kinase Lyn with either one or both of the compounds of the present invention. The activated kinase phosphorylates the insulin receptor substrate 1 (IRS-1), which triggers several signaling pathways that are involved in the regulation of glucose production, transportation, and cellular utilization.
According to one aspect, the present invention provides a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent for use in the treatment of type II diabetes and/or a medical condition associated with type II diabetes.
According to some embodiments, the N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is in the form of a substantially pure stereoisomer or a combination of stereoisomers.
According to further embodiments, said N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is selected from N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((S)- l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and a combination thereof.
In one embodiment, the N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2- yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide. In another embodiment, the N-(l- (4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide.
In one embodiment, the stereoisomer comprises at least about 90% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 10% of other stereoisomeric forms of the compound.
In another embodiment, the stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-
2- yl)-3-phenylpropanamide or a combination thereof, and less than about 5% of other stereoisomeric forms of the compound.
In one currently preferred embodiment, the stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-
3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a combination thereof, and less than about 2% of other stereoisomeric forms of the compound.
According to some embodiments, the composition is in the form of a capsule, tablet, granule, powder, solution or suspension.
According to some embodiments, the pharmaceutical composition is in a form suitable for intravenous, intramuscular, oral, sublingual, buccal, parenteral, intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal administration.
According to another aspect, the present invention contemplates a method for treating type II diabetes and/or a medical condition associated with type II diabetes in a subject in need thereof, comprising the step of administering to said subject a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent.
According to some embodiments, said treating comprises any one or more of alleviating, preventing, delaying the onset, attenuating the progression of type II diabetes or conditions associated with this disease and achieving a beneficial therapeutic effect for a sustained period of time.
According to some embodiments, the medical condition associated with type II diabetes is selected from the group consisting of hyperglycemia, insulin resistance, impaired glucose tolerance, fatty liver, metabolic syndrome X, obesity, cancer, microvascular complications including neuropathy (nerve damage), nephropathy (kidney disease), vision disorders (e.g., retinopathy, glaucoma, cataract and corneal
disease), macrovascular complications including heart disease, stroke, peripheral vascular disease, infections, metabolic difficulties, impotence, autonomic neuropathy and pregnancy complications.
According to some embodiments, the subject is a mammal, preferably a human. In another aspect, the present invention relates to the use of a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide as described herein, for the manufacture of a medicament for treating type II diabetes and/or a medical condition associated with type II diabetes.
The present invention will be more fully understood from the following figures and detailed description of the preferred embodiments thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
Figs. 1A-1D show Oil-Red stained human subcutaneous pre-adipocytes (A xlO; B x20) and human subcutaneous differentiated adipocytes (C xlO; D x20).
Figs. 2A-2B are bar charts representing the glucose uptake level in adipocytes, in vitro, in the presence of different concentrations of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide (Fig. 2A; (S,S); relative to insulin performance) and N-((S)- l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2- yl)-3 -phenylpropanamide (Fig. 2B; (S,R); relative to insulin performance). In both charts the two left columns depict control experiments, in which cultures were treated with 100 nM insulin or 10 μΜ of Rosiglitazone.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to pharmaceutical compositions comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide for use in the treatment of type II diabetes and/or related medical conditions, e.g., hyperglycemia, insulin resistance and impaired glucose tolerance, among others.
According to some embodiments, the present invention provides a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-
hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent for use in the treatment of type II diabetes and/or a medical condition associated with type II diabetes.
According to some embodiments, the N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is in the form of a substantially pure stereoisomer or a combination of stereoisomers.
According to some embodiments, said N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is selected from N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((S)- l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and a combination thereof.
The stereoisomers N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and N-((S)- 1 -(4-hydroxyphenyl)- 3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide are represented by formula (II) and formula (III), respectively:
(Π)
In one embodiment, the N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2- yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide. In another embodiment, the N-(l- (4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide. In another embodiment, the composition of the invention comprises a combination of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and N-((S)- 1 -(4-hydroxyphenyl)- 3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.
Chemical Definitions
The term "stereoisomers" as used herein, refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. In particular, "enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another. Enantiomers have identical chemical and physical properties except for their ability to rotate plane- polarized light (+/-) by equal amounts but in opposite directions. "Diastereomers", on the other hand, refers to stereoisomers with two or more centers of asymmetry and whose molecules are not mirror images of one another. Diastereomers are characterized by differences in physical properties (e.g., melting points, boiling points and spectral properties) and by some differences in chemical behavior towards achiral as well as chiral reagents. The terms "diastereomers" and "diastereoisomer" as used herein, are interchangeable.
Stereochemical definitions used herein generally follow McGraw-Hill Dictionary of Chemical Terms, S. P. Parker, Ed., McGraw-Hill Book Company, New York (1984) and Stereochemistry of Organic Compounds, Eliel, E. L. and Wilen, S. H., John Wiley & Sons, Inc., New York (1994).
All stereoisomers of the compound of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compound can exist in enantiomeric and/or diastereomeric forms or in mixtures thereof. The present invention intends to the use of any enantiomerically or diastereomerically enriched mixtures (i.e.,
mixtures enriched for one enantiomer or diastereomer), substantially pure enantiomers or diastereomers, or any mixtures thereof. The chiral centers can be designated as R or S.
The compound of the invention may be present as a salt. The term "salt" encompasses both basic and acid addition salts, including but not limited to phosphate, dihydrogen phosphate, hydrogen phosphate and phosphonate salts, and include salts formed with organic and inorganic anions and cations. Furthermore, the term includes salts that form by standard acid-base reactions of basic groups and organic or inorganic acids. Such acids include hydrochloric, hydrofluoric, hydrobromic, trifluoroacetic, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, cholic, pamoic, mucic, D-camphoric, phthalic, tartaric, salicyclic, methanesulfonic, benzenesulfonic, p- toluenesulfonic, sorbic, picric, benzoic, cinnamic, and like acids. Additional salts of the compound described herein may be prepared by reacting the parent molecule with a suitable base, e.g., NaOH or KOH to yield the corresponding alkali metal salts, e.g., the sodium or potassium salts. Additional basic addition salts include ammonium salts (NH/t+), substituted ammonium salts, Li, Ca, Mg, salts, and the like.
The compound of the invention may be present as a hydrate. The term "hydrate" refers to a solvate wherein the solvent molecule is water. The term "Solvate" contemplates a physical association of the compound of the invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation.
As used herein, the term "substantially pure" generally refers to the presence of at least about 80% of a single stereoisomer, preferably at least about 90% more preferably at least about 95% or 97% and most preferably at least about 98% or 99% of a single stereoisomer.
According to some embodiments, the compositions of the invention comprise substantially pure N-((S)- 1 -(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide. According to some specific embodiments, the substantially pure stereoisomer comprises at least about 80% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 20% of other stereoisomeric forms of the compound. According to other
embodiments, the substantially pure stereoisomer comprises at least about 90% by weight of N-((S)- 1 -(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide, and less than about 10% of other stereoisomeric forms of the compound. According to currently preferred embodiments, the substantially pure stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3- ((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 5% of other stereoisomeric forms of the compound. According to other preferred embodiments, the substantially pure stereoisomer comprises at least about 97% by weight of N-((S)- 1 -(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide, and less than about 3% of other stereoisomeric forms of the compound. According to yet other preferred embodiments, the substantially pure stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3- ((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 2% of other stereoisomeric forms of the compound. According other preferred embodiments, the substantially pure stereoisomer comprises at least about 99% by weight of N-((S)-1- (4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 1 % of other stereoisomeric forms of the compound.
According to other embodiments, the compositions of the invention comprise substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)- 3-phenylpropanamide. According to some specific embodiments, the substantially pure stereoisomer comprises at least about 80% by weight of N-((S)-l-(4-hydroxyphenyl)-3- ((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 20% of other stereoisomeric forms of the compound. According to other embodiments, the substantially pure stereoisomer comprises at least about 90% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 10% of other stereoisomeric forms of the compound. According to currently preferred embodiments, the substantially pure stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 5% of other stereoisomeric forms of the compound. According to other preferred embodiments, the substantially pure stereoisomer comprises at least about 97% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and
less than about 3% of other stereoisomeric forms of the compound. According to yet other preferred embodiments, the substantially pure stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 2% of other stereoisomeric forms of the compound. According to other preferred embodiments, the substantially pure stereoisomer comprises at least about 99% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, and less than about 1 % of other stereoisomeric forms of the compound.
According to yet other embodiments, the compositions of the invention comprise a mixture of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide and N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.According to some embodiments, the stereoisomer comprises at least about 80% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or N- ((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or a combination thereof, and less than about 20% of other stereoisomeric forms of the compound.
According to some embodiments, the stereoisomer comprises at least about 90% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 10% of other stereoisomeric forms of the compound.
According to some embodiments, the stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 5% of other stereoisomeric forms of the compound.
According to some embodiments, the stereoisomer comprises at least about 97% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-
2-yl)-3-phenylpropanamide or a combination thereof, and less than about 3% of other stereoisomeric forms of the compound.
According to some embodiments, the stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 2% of other stereoisomeric forms of the compound.
According to some embodiments, the stereoisomer comprises at least about 99% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide or a combination thereof, and less than about 1% of other stereoisomeric forms of the compound.
According to some embodiments the at least one other stereoisomer is selected from the group consisting of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((S)- 1 -(4-hydroxyphenyl)-3- ((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((R)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((R)- l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or combination thereof.
Methods to obtain stereochemically purity compounds, such as classical separation techniques and stereochemically controlled synthesis are well known in the art (see e.g., Enantiomers, Racemates and Resolutions, Jacques J., Collet A. and Wilen S. H., John Wiley & Sons, Inc., New York (1981)). WO 2013/084238 for example, discloses a stereochemically controlled synthesis of N-((S)-l-(4-hydroxyphenyl)-3- ((S)-2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide. The prevailing racemization was overcome by controlling the reaction temperature and the order of adding the raw materials. WO 2013/084238 also demonstrates a method of separation of the two diastereomers prepared as a mixture in the traditional synthesis (described for example, in US 2011/0086910), by a supercritical fluid chromatography (SFC) on RegisPack™, a polysaccharide coated chiral column. The contents of WO 2013/084238 are hereby incorporated by reference in their entirety.
Therapeutic Use
According to some embodiments, the present invention provides a method for treating type II diabetes and/or a medical condition associated with type II diabetes in a subject in need thereof, comprising the step of administering to said subject a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent.
The terms "treating" and "treatment", as used herein are interchangeable and refer to any one or more of delaying the onset of, retarding or reversing the progress of, alleviating or preventing either type II diabetes or one or more medical conditions associated with of such disease, and achieving a beneficial therapeutic effect preferably for a sustained or prolonged period of time. Each possibility is a separate embodiment of the invention.
According to some embodiments, the medical condition associated with type II diabetes is selected from the group consisting of glucose and insulin metabolism deficiencies, diabetic complications and metabolic disorders.
Non limiting examples of medical conditions associated with type II diabetes include hyperglycemia, insulin resistance, impaired glucose tolerance, fatty liver, metabolic syndrome X, obesity, cancer, microvascular complications including neuropathy (nerve damage), nephropathy (kidney disease) and vision disorders (e.g., retinopathy, glaucoma, cataract and corneal disease), macrovascular complications including heart disease, stroke and peripheral vascular disease (which can lead to ulcers, gangrene and amputation) among others. Each possibility is a separate embodiment of the invention.
Other medical conditions associated with type II diabetes, include but are not limited to, infections, metabolic difficulties, impotence, autonomic neuropathy and pregnancy complications.
As used herein, the term "administering" refers to bringing in contact with a compound of the present invention. Administration can be accomplished to cells or tissue cultures, or to living organisms, for example humans.
According to some embodiments, the subject is a mammal, preferably a human.
According to some embodiments, the present invention relates to the use of a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide as described herein, in the manufacture of a medicament for treating type II diabetes and/or a medical condition associated with type II diabetes.
The method of treatment of the invention may be in parallel to, prior to, or following additional method of treatment.
According to some embodiments, the composition of the present invention may be administered to a subject in need as a prodrug. The prodrug often offers advantages such as delayed release, solubility, and/or tissue compatibility. The term "prodrug", as used herein, refers to the compound of the present invention that when administered generates the biologically active "drug'Vcomposition as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s). The prodrug and derivatives thereof may be prepared by methods and techniques known to those of skill in the art.
The present invention further provides the administration of the pharmaceutical compositions of the present invention in combination with at least one additional antidiabetic medication. The combination therapy may be administered to the subject undergoing treatment simultaneously or sequentially in any order, at a time interval determined by a skilled artisan.
Non-limiting examples of anti-diabetic medication include insulin, secretagogues (such as sulfonylureas and nonsulfonylurea secretagogues), alpha-glucosidase inhibitors, biguanides, meglitinides, and thiazolidinediones, sensitizers (such as biguanides and thiazolidinediones), peptide analogs (such as injectable incretin mimetics and injectable Amylin analogues), among others. Each possibility represents a separate embodiment of the invention.
Non-limiting examples of known anti-diabetic drugs include Metformin, rosiglitazone (Avandia), pioglitazone (Actos), tolbutamide (Orinase),acetohexamide (Dymelor), tolazamide (Tolinase), chlorpropamide (Diabinese), Second-generation agents, glipizide (Glucotrol), glyburide (Diabeta, Micronase, Glynase), glimepiride (Amaryl), gliclazide (Diamicron), repaglinide (Prandin), nateglinide (Starlix), miglitol (Glyset), acarbose (Precose/Glucobay), Exenatide, Liraglutide, vildagliptin (Galvus),
sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta) among others. Each possibility represents a separate embodiment of the invention.
Pharmaceutical Composition
According to some embodiments, the pharmaceutical composition of the present invention can be formulated for administration by a variety of routes selected from the group consisting of intravenous, intramuscular, oral, sublingual, buccal, parenteral, , intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal among others. Each possibility is a separate embodiment of the invention.
Such composition is prepared in a manner well known in the pharmaceutical art and comprise as the active ingredient one or more stereoisomers of N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide as described hereinabove, and a pharmaceutically acceptable excipient and/or carrier. The term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U. S. Pharmacopeia or other generally recognized pharmacopeia for use in animals and, more particularly, in humans.
The pharmaceutical composition of the invention is suitable for use in a variety of drug delivery systems as detailed hereinbelow. Pharmaceutically acceptable carriers suitable for use in the present invention may be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985).
During the preparation of the pharmaceutical composition according to the present invention the active ingredient is usually mixed with a carrier and/or excipient, which may be a solid, semi-solid, or liquid material. The composition is preferably suited for oral administration, in which case it may be in the form of a tablet, pill, pellet, chewable tablet, capsule, granule, powder, lozenge, sachet, cachet, elixir, suspension, transdermal patch, dispersion, emulsion, solution, syrup, intranasal spray, aerosol (as a solid or in a liquid medium), ointment (containing, for example, up to 10% by weight of the active compound), soft and hard gelatin capsule, suppositorie, sterile injectable solution and sterile packaged powder among other. Each possibility is a separate embodiment of the invention. In another embodiment, the compound of the present invention may be added to a person's diet by mixing them with food or drink.
The carrier may be any of those conventionally used. The choice of carrier will be determined by the particular method used to administer the pharmaceutical
composition. Some examples of suitable carriers include lactose, glucose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water and methylcellulose. Other pharmaceutical carriers may be sterile liquids, such as water, alcohols (e.g., ethanol) and lipid carriers such as oils (including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like), phospholipids (e.g. lecithin), polyethylene glycols, glycerine, propylene glycol or other synthetic solvents. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
The formulations may additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents, surfactants, emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; flavoring agents, colorants, buffering agents (e.g., acetates, citrates or phosphates), disintegrating agents, moistening agents and agents for the adjustment of tonicity such as sodium chloride. Fatty acids may also be included.
Alternative formulations include immediate-release formulations, slow-release formulations, controlled-release formulations, sustained-release formulations, extended-release formulations, delayed-release formulations and the like, as are known in the art. Each possibility is a separate embodiment of the invention.
The amount of the active ingredient that will be effective in the treatment of type II diabetes will depend on the severity of the disease, and may be determined by standard non-clinical or clinical techniques. The precise dose to be employed in the formulation will also depend on the route of administration, the seriousness of the disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. A preferred dosage will be within the range of 0.01-1000 mg/kg of body weight, more preferably, about 0.1 mg/kg to about 100 mg/kg and even more preferably about 1 mg/kg to about 10 mg/kg. Applicable methods for determining an appropriate dose and dosing schedule for administration of the present invention are known in the art and are described, for example, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Brunton. L., Chabner B., and Knollman B., McGraw-Hill (2006), and in Remington: The Science and Practice of Pharmacy, Troy
D. B., and Beringer P., Lippencott Williams & Wilkins (2003).
The examples hereinbelow are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art may readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.
EXAMPLES
Example 1: The effect of N-«S)-l-(4-hydroxyphenyl)-3-«S)-2- hvdroxypropoxy)propan-2-yl)-3-phenylpropanamide and N-((S)-l-(4- hvdroxyphenyl)-3-((R)-2-hvdroxypropoxy)propan-2-yl)-3-phenylpropanamide on glucose uptake in vitro
The effects of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2- yl)-3-phenylpropanamide and N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide on glucose uptake was determined in vitro using human subcutaneous adipocytes.
N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide and N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide were provided by Novaremed. Each compound was dissolved in DMSO (10 mM stock solution) and stored at -20°C until use.
Human Subcutaneous Preadipocytes (HP A), isolated from human subcutaneous fat tissues were purchased from Innoprot. The cells were cultured in preadipocyte medium in 96 well plates in a humidified atmosphere of 5% CO2 at 37 °C. After confluence, the cells were incubated in differentiation medium for two days. The medium was then changed to Dulbecco's Modified Eagle medium (DMEM), a medium containing 10 μg/ml insulin, for another two days. The cells were allowed to differentiate for six days before glucose uptake experiments. As shown in Figure 1 , pre- adipocytes (Fig. 1A; xlO and Fig. IB; x20) and differentiated adipocytes (Fig. 1C; xlO and Fig. ID; x20), stained with Oil-Red. The mature adipocytes were incubated for two h with PBS at 37 °C to deplete them from glucose. Following incubation for 60 min
with PBS containing 80 mM of 2-[N-(7-nitrobenz-2-oxa-l, 3-diazol-4-yl) amino] -2- deoxy-D -glucose (2-NBDG; a fluorescent glucose analog) and different concentrations of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan- 2-yl)-3-phenylpropanamide. Control cultures were treated with 100 nM insulin or 10 μΜ of Rosiglitazone (RGT), a PPARy agonist. After incubation, free 2-NBDG was washed out from the cultures and the remaining fluorescence monolayer in the cell was measured with a Tecan-GENios fluorescence reader (Tecan). Excitation wavelength was set to 460 nm and an emission wavelength to 540 nm. Values of 2-NBDG incorporation in the absence of insulin were subtracted from those obtained with 100 nM insulin to establish 100% of specific 2-NBDG uptake.
Figures 2A-B demonstrate that both compounds induced glucose uptake in a biphasic manner. However, N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide (Fig. 2B) may be therapeutically advantageous over N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2- yl)-3-phenylpropanamide (Fig. 2A) as with merely 0.25 μΜ of the former a substantial glucose uptake was achieved, while a similar effect was obtained with about 100 μΜ of the later.
The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.
Claims
A pharmaceutical composition comprising one or more stereoisomers of N- (l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent, for use in the treatment of type II diabetes and/or a medical condition associated with type II diabetes.
The pharmaceutical composition according to claim 1, wherein the N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is in the form of a substantially pure stereoisomer or a combination of stereoisomers.
The pharmaceutical composition according to claim 2, wherein the N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is selected from N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide, N-((S)- 1 -(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide and a combination thereof.
The pharmaceutical composition according to claim 3, wherein the N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.
The pharmaceutical composition according to claim 3, wherein the N-(l-(4- hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide.
The pharmaceutical composition according to claim 2, wherein the stereoisomer comprises at least about 90% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a combination thereof, and less than about 10% of other stereoisomeric forms of the compound.
7. The pharmaceutical composition according to claim 6, wherein the stereoisomer comprises at least about 95% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a combination thereof, and less than about 5% of other stereoisomeric forms of the compound.
8. The pharmaceutical composition according to claim 7, wherein the stereoisomer comprises at least about 98% by weight of N-((S)-l-(4- hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or N-((S)-l-(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a combination thereof, and less than about 2% of other stereoisomeric forms of the compound.
9. The pharmaceutical composition according to claim 1, wherein the medical condition associated with type II diabetes is selected from the group consisting of hyperglycemia, insulin resistance, impaired glucose tolerance, fatty liver, metabolic syndrome X, obesity, cancer, microvascular complications including neuropathy (nerve damage), nephropathy (kidney disease), vision disorders (e.g., retinopathy, glaucoma, cataract and corneal disease), macrovascular complications including heart disease, stroke, peripheral vascular disease, infections, metabolic difficulties, impotence, autonomic neuropathy and pregnancy complications.
10. The pharmaceutical composition according to claim 1, wherein the composition is in the form of a capsule, tablet, granule, powder, solution or suspension.
11. The pharmaceutical composition according to claim 1 , in a form suitable for intravenous, intramuscular, oral, sublingual, buccal, parenteral, , intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal administration.
12. A method for treating type II diabetes and/or a medical condition associated with type II diabetes in a subject in need thereof, comprising the step of
administering to said subject a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent.
13. The method according to claim 12, wherein the N-(l-(4-hydroxyphenyl)-3- (2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is in the form of a substantially pure stereoisomer or a combination of stereoisomers.
14. The method according to claim 13, wherein the N-(l-(4-hydroxyphenyl)-3- (2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is selected from N- ((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide, N-((S)- 1 -(4-hydroxyphenyl)-3-((R)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide and a combination thereof.
15. The method according to claim 14, wherein the N-(l-(4-hydroxyphenyl)-3- (2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((S)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide.
16. The method according to claim 14, wherein the N-(l-(4-hydroxyphenyl)-3- (2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide is substantially pure N-((S)-l-(4-hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide.
17. The method according to claim 13, wherein the stereoisomer comprises at least about 90% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or a combination thereof, and less than about 10% of other stereoisomeric forms of the compound.
18. The method according to claim 17, wherein the stereoisomer comprises at least about 95% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3-
phenylpropanamide or a combination thereof, and less than about 5% of other stereoisomeric forms of the compound.
19. The method according to claim 18, wherein the stereoisomer comprises at least about 98% by weight of N-((S)-l-(4-hydroxyphenyl)-3-((S)-2- hydroxypropoxy)propan-2-yl)-3-phenylpropanamide or N-((S)-l-(4- hydroxyphenyl)-3-((R)-2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or a combination thereof, and less than about 2% of other stereoisomeric forms of the compound.
20. The method according to claim 12, wherein treating comprises at least one of alleviating, preventing, delaying the onset, attenuating the progression of type II diabetes and/or medical condition associated with type II diabetes and achieving a beneficial therapeutic effect.
21. The method according to claim 12, wherein the subject is a mammal.
22. The method according to claim 21, wherein the subject is human.
23. The method according to claim 12, wherein the pharmaceutical composition is administered in a route of administration selected from the group consisting of intravenous, intramuscular, oral, sublingual, buccal, parenteral, intramuscular, inhalation, intraperitoneal, nasal, subcutaneous, topical, intradermal or transdermal.
24. The method according to claim 12, wherein the medical condition associated with type II diabetes is selected from the group consisting of hyperglycemia, insulin resistance, impaired glucose tolerance, fatty liver, metabolic syndrome X, obesity, cancer, microvascular complications including neuropathy (nerve damage), nephropathy (kidney disease), vision disorders (e.g., retinopathy, glaucoma, cataract and corneal disease), macrovascular complications including heart disease, stroke, peripheral vascular disease, infections, metabolic difficulties, impotence, autonomic neuropathy and pregnancy complications.
25. Use of a pharmaceutical composition comprising one or more stereoisomers of N-(l-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3- phenylpropanamide or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent, for the manufacture of
a medicament for the treatment of type II diabetes and/or a medical condition associated with type II diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461992922P | 2014-05-14 | 2014-05-14 | |
US61/992,922 | 2014-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015173813A1 true WO2015173813A1 (en) | 2015-11-19 |
Family
ID=54479404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2015/050499 WO2015173813A1 (en) | 2014-05-14 | 2015-05-12 | Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015173813A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031129A2 (en) * | 2002-10-03 | 2004-04-15 | New Era Biotech, Ltd. | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
WO2013042005A1 (en) * | 2011-09-21 | 2013-03-28 | Novaremed Ltd | N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
WO2013084238A1 (en) * | 2011-12-08 | 2013-06-13 | Novaremed Ltd. | Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide |
-
2015
- 2015-05-12 WO PCT/IL2015/050499 patent/WO2015173813A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031129A2 (en) * | 2002-10-03 | 2004-04-15 | New Era Biotech, Ltd. | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
WO2013042005A1 (en) * | 2011-09-21 | 2013-03-28 | Novaremed Ltd | N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
WO2013084238A1 (en) * | 2011-12-08 | 2013-06-13 | Novaremed Ltd. | Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2275108B1 (en) | Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form | |
US20090324701A1 (en) | Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders | |
US11034691B2 (en) | Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders | |
WO2012067111A1 (en) | PKC-ε ACTIVATOR | |
US8440678B2 (en) | Pharmaceutical composition | |
TW201206443A (en) | Treatment of Type 2 diabetes | |
CN115348863A (en) | Treatment of type 2 diabetes or obesity or excess body weight with 2- [ (4- {6- [ (4-cyano-2-fluorobenzyl) oxy ] pyridin-2-yl } piperidin-1-yl) methyl ] -1- [ (2S) -oxetan-2-ylmethyl ] -1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
TW202308620A (en) | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor and preparation thereof | |
WO2015173813A1 (en) | Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes | |
US9649294B2 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
WO2023129595A1 (en) | Obicetrapib and sglt2 inhibitor combination | |
US9468669B2 (en) | Methods to treat dysregulated blood glucose disorders | |
US20210206773A1 (en) | Drug for treating disorders of corneal epithelium | |
JP2010516716A (en) | Use of catecholamines and related compounds as angiogenesis inhibitors | |
EP3996704A1 (en) | Combination therapy of gpr119 agonists and dpp-4 inhibitors | |
CA3102407A1 (en) | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | |
CA3102584A1 (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
TWI842924B (en) | Pharmaceutical combination and pharmaceutical kit of gpr119 agonists and dpp-4 inhibitors | |
RU2818562C2 (en) | Combined therapy with gpr119 agonists and dpp-4 inhibitors | |
US20160166578A1 (en) | Method for treating type i and type ii diabetes | |
US20240009195A1 (en) | Novel uses | |
US20230414621A1 (en) | No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15792863 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15792863 Country of ref document: EP Kind code of ref document: A1 |